Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expression in pancreatic ductal adenocarcinoma
Open Access
- 6 February 2026
- journal article
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Abstract
GATA6 promotes epithelial phenotypes and limits epithelial-to-mesenchymal (EMT) transition in pancreatic ductal adenocarcinoma (PDAC). Here we show that GATA6 defines a tumor cell state that induces MHCI expression and anti-tumor cytotoxicity upon therapy. In human PDAC, GATA6 expression correlates with immune cell infiltration, and spatial analysis reveals interaction between GATA6 + tumor cells and CD8 + T cells. In murine PDAC, MEK inhibition (MEKi) enriches antigenicity-related gene sets in GATA6 high cells, while GATA6 knockout or degradation impairs MEKi-induced MHCI upregulation. High-GATA6 tumors respond to MEKi with increased MHCI, enhancing T-cell cytotoxicity, whereas GATA6 loss abolishes this effect. Treatment-induced EMT reduces GATA6 + populations and MHCI expression, which is restored by combining MEKi with HDAC inhibitors, enhancing GATA6 + tumor cells, MHCI, CD8 + T cell infiltration, tumor suppression, and survival. These findings suggest that therapeutic strategies promoting a GATA6-driven tumor cell state improve immune recognition of PDAC cells and potentiate anti-tumor cytotoxic effects.Keywords
All Related Versions
Funding Information
- Bundesministerium für Forschung, Technologie und Raumfahrt (01KD2206A/SATURN3)
- EC | Seventh Framework Programme (602783)
- Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen (CANcer TARgeting (CANTAR))
- Deutsche Forschungsgemeinschaft (418179183)
- Deutsche Forschungsgemeinschaft (421166016)
- Deutsche Forschungsgemeinschaft (450917483)
- Deutsche Krebshilfe (70115201)
- Deutsches Krebsforschungszentrum (DKTK)
- Deutsches Konsortium für translationale Krebsforschung
This publication has 64 references indexed in Scilit:
- PLK1 blockade enhances the anti-tumor effect of MAPK inhibition in pancreatic ductal adenocarcinomaCell Reports, 2025
- Hourglass, a rapid analysis framework for heterogeneous bioimaging data, identifies sex disparity in IL‐6/STAT3‐associated immune phenotypes in pancreatic cancerThe Journal of Pathology, 2023
- Epigenetic control of pancreatic cancer metastasisCancer and Metastasis Reviews, 2023
- Microenvironment drives cell state, plasticity, and drug response in pancreatic cancerCell, 2021
- Spatially confined sub-tumor microenvironments in pancreatic cancerCell, 2021
- Cholesterol Pathway Inhibition Induces TGF-β Signaling to Promote Basal Differentiation in Pancreatic CancerCancer Cell, 2020
- Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in OncologyDrug Safety, 2019
- Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior TherapyJAMA Oncology, 2017
- Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancerTargeted Oncology, 2016
- HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMTJournal of Cellular Physiology, 2010